Showing 13–24 of 99 results
The webinar focusses on measuring antibody-mediated cell death using DiscoverX’s KILR Bioassays, and how they can be used to measure…
Watch NowWith more than 25% of the world’s population diagnosed with type II diabetes and/or metabolic syndrome, the requirement for cost…
Read MoreLigand-induced receptor dimerization is an early functional step in receptor activation, representing the most proximal, functional read-out for Interleukin receptors.…
Read MoreClass I therapeutic antibodies achieve their clinical efficacy not only by binding to their target antigen, but also through Fc…
Read MoreAssays that directly detect compound binding inside cells can be of great utility in translating in vitro data to more…
Read MoreLigand-induced receptor dimerization is an early functional step in receptor activation, representing the most proximal, functional readout for Interleukin receptors.…
Read MoreLigand-induced receptor dimerization is an early functional step in receptor activation, representing the most proximal, functional read-out for Interleukin receptors.…
Read MoreSuccess of ADCC assays is highly dependent on the quality of effector cells used. However, human primary cells (such as…
Read MoreDiscoverX PEGS 2017 Presentation Presented By: Jane Lamerdin, Ph.D.
Read MoreDiscoverX CASSS 2017 Presentation Presented by Dr. Jane Lamerdin, Director R&D, DiscoverX May 9, 2017
Read MoreWatch Recorded Presentation Jane Lamerdin, Ph.D. Director R&D, Eurofins DiscoverX
Read MoreRobust, Ready-to-Use ADCC & ADCP Bioassays to Accelerate Your Drug Development Program The KILR® cytotoxicity assay platform developed by Eurofins…
Read More
